Cynata Therapeutics Limited (CYYNF)
USD 0.19
(0.0%)
USD 0.19
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -9.74 Million AUD | 31.75% |
| 2023 | -14.27 Million AUD | -162.2% |
| 2022 | -5.44 Million AUD | 29.19% |
| 2021 | -7.68 Million AUD | -111.31% |
| 2020 | -3.63 Million AUD | 57.05% |
| 2019 | -8.47 Million AUD | -85.54% |
| 2018 | -4.56 Million AUD | -0.28% |
| 2017 | -4.55 Million AUD | 7.81% |
| 2016 | -4.93 Million AUD | -33.06% |
| 2015 | -3.71 Million AUD | -22.12% |
| 2014 | -3.03 Million AUD | -231.95% |
| 2013 | -915.7 Thousand AUD | 40.63% |
| 2012 | -1.54 Million AUD | 39.87% |
| 2011 | -2.56 Million AUD | -21.21% |
| 2010 | -2.11 Million AUD | -92.15% |
| 2009 | -1.1 Million AUD | 25.93% |
| 2008 | -1.48 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -5.2 Million AUD | 0.0% |
| 2024 Q1 | -2.27 Million AUD | 75.06% |
| 2024 Q2 | -4.54 Million AUD | -100.0% |
| 2024 FY | -9.74 Million AUD | 31.75% |
| 2023 FY | -14.27 Million AUD | -162.2% |
| 2023 Q1 | -2.58 Million AUD | 40.04% |
| 2023 Q3 | -4.55 Million AUD | 12.0% |
| 2023 Q4 | -9.1 Million AUD | -100.0% |
| 2023 Q2 | -5.17 Million AUD | -100.0% |
| 2022 Q3 | -2.15 Million AUD | -90.68% |
| 2022 Q2 | -1.13 Million AUD | -100.0% |
| 2022 FY | -5.44 Million AUD | 29.19% |
| 2022 Q1 | -565.59 Thousand AUD | 80.16% |
| 2022 Q4 | -4.31 Million AUD | -100.0% |
| 2021 Q2 | -4.83 Million AUD | -100.0% |
| 2021 Q1 | -2.41 Million AUD | -121.91% |
| 2021 FY | -7.68 Million AUD | -111.31% |
| 2021 Q3 | -1.42 Million AUD | 70.55% |
| 2021 Q4 | -2.85 Million AUD | -100.0% |
| 2020 Q4 | -1.09 Million AUD | -100.0% |
| 2020 Q1 | -1.27 Million AUD | 76.79% |
| 2020 FY | -3.63 Million AUD | 57.05% |
| 2020 Q2 | -2.54 Million AUD | -100.0% |
| 2020 Q3 | -545.21 Thousand AUD | 78.61% |
| 2019 Q1 | -1.49 Million AUD | -8.37% |
| 2019 Q2 | -1.49 Million AUD | 0.0% |
| 2019 FY | -8.47 Million AUD | -85.54% |
| 2019 Q4 | -5.49 Million AUD | -100.0% |
| 2019 Q3 | -2.74 Million AUD | -84.25% |
| 2018 Q4 | -1.37 Million AUD | 0.0% |
| 2018 Q2 | -907.85 Thousand AUD | 0.0% |
| 2018 Q1 | -907.85 Thousand AUD | 48.6% |
| 2018 FY | -4.56 Million AUD | -0.28% |
| 2018 Q3 | -1.37 Million AUD | -51.48% |
| 2017 Q4 | -1.76 Million AUD | 0.0% |
| 2017 FY | -4.55 Million AUD | 7.81% |
| 2017 Q1 | -510.68 Thousand AUD | 58.67% |
| 2017 Q3 | -1.76 Million AUD | -245.83% |
| 2017 Q2 | -510.68 Thousand AUD | 0.0% |
| 2016 FY | -4.93 Million AUD | -33.06% |
| 2016 Q2 | -1.23 Million AUD | 0.0% |
| 2016 Q1 | -1.23 Million AUD | -7.62% |
| 2016 Q4 | -1.23 Million AUD | 0.0% |
| 2016 Q3 | -1.23 Million AUD | -0.12% |
| 2015 Q3 | -1.14 Million AUD | -61.65% |
| 2015 Q4 | -1.14 Million AUD | 0.0% |
| 2015 Q2 | -709.36 Thousand AUD | 0.0% |
| 2015 Q1 | -709.36 Thousand AUD | -8.13% |
| 2015 FY | -3.71 Million AUD | -22.12% |
| 2014 Q4 | -656.05 Thousand AUD | 0.0% |
| 2014 Q3 | -656.05 Thousand AUD | 24.05% |
| 2014 Q2 | -863.78 Thousand AUD | 0.0% |
| 2014 Q1 | -863.78 Thousand AUD | -222.85% |
| 2014 FY | -3.03 Million AUD | -231.95% |
| 2013 Q4 | -267.55 Thousand AUD | 0.0% |
| 2013 FY | -915.7 Thousand AUD | 40.63% |
| 2013 Q3 | -267.55 Thousand AUD | 0.0% |
| 2012 FY | -1.54 Million AUD | 39.87% |
| 2011 FY | -2.56 Million AUD | -21.21% |
| 2010 FY | -2.11 Million AUD | -92.15% |
| 2009 FY | -1.1 Million AUD | 25.93% |
| 2008 FY | -1.48 Million AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 87.001% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -48.183% |
| SQZ Biotechnologies Company | -79.46 Million USD | 87.737% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 118.394% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 114.961% |
| Mesoblast Limited | -87.95 Million USD | 88.921% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -435.268% |
| Genus plc | 7.9 Million USD | 223.351% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 10.531% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -162.644% |
| Marizyme, Inc. | -65.34 Million USD | 85.088% |
| ContraFect Corporation | -65.15 Million USD | 85.043% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -10.184% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -99.439% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -464.108% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -236.908% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -20.907% |
| MultiCell Technologies, Inc. | -380.07 USD | -2563824.803% |
| Accustem Sciences Inc. | -3.74 Million USD | -160.107% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 81.149% |
| EV Biologics, Inc. | -1.26 Million USD | -669.035% |
| Q BioMed Inc. | -2.05 Million USD | -374.867% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -161.042% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1440.892% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -309.292% |
| Biomind Labs Inc. | -1.21 Million USD | -702.483% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 7.616% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -23.302% |
| Skye Bioscience, Inc. | -37.64 Million USD | 74.114% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -349.103% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -64968.837% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -39.552% |
| IMV Inc. | -36.48 Million USD | 73.292% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 38.602% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -67.514% |
| GB Sciences, Inc. | -1.36 Million USD | -615.64% |
| Alpha Cognition Inc. | -13.77 Million USD | 29.246% |
| HST Global, Inc. | -146.21 Thousand USD | -6564.872% |
| CSL Limited | 2.64 Billion USD | 100.369% |
| Halberd Corporation | -79.67 Thousand USD | -12130.419% |
| Enzolytics Inc. | -2.17 Million USD | -347.656% |
| Resverlogix Corp. | -3.61 Million USD | -169.937% |
| Affymax, Inc. | -14.42 Million USD | 32.441% |
| SYBLEU INC | -180.3 Thousand USD | -5304.599% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -207.265% |
| argenx SE | -295.05 Million USD | 96.697% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 84.433% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 10043.581% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -145.274% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -222.018% |
| AVAX Technologies, Inc. | -6.41 Million USD | -51.937% |
| Zenith Capital Corp. | -10.59 Million USD | 8.034% |
| Genscript Biotech Corporation | -95.47 Million USD | 89.794% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -41827.153% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -135.042% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -16022.784% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 83.684% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -214.166% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -822.745% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -399.921% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -155.164% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -385.993% |
| BioStem Technologies, Inc. | -8.48 Million USD | -14.874% |
| ONE Bio Corp. | 8.67 Million USD | 212.31% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2107.837% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -629.705% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -455.327% |
| Agentix Corp. | -1.37 Million USD | -609.113% |
| LadRx Corporation | 400.44 Thousand USD | 2533.482% |
| Cell Source, Inc. | -5.32 Million USD | -83.13% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2245.416% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1052.089% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1052.089% |
| NovAccess Global Inc. | -4.76 Million USD | -104.326% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 240.726% |
| Itoco Inc. | -1.86 Million USD | -421.388% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -119.35% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -483.865% |
| Kadimastem Ltd | -3.3 Million USD | -194.634% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3464.242% |
| CytoDyn Inc. | -49.84 Million USD | 80.448% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -12229.924% |
| Mobile Lads Corp. | -2.26 Million USD | -330.555% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -4171.616% |
| Qrons Inc. | -789.34 Thousand USD | -1134.528% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -934.988% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -366.772% |
| Rebus Holdings, Inc. | -1.02 Million USD | -855.364% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -504.234% |
| International Stem Cell Corporation | -131 Thousand USD | -7338.709% |
| Bioxytran, Inc. | -4.28 Million USD | -127.68% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -17855.316% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -285.129% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 79.729% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -360.961% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1147.903% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -207.598% |
| Neutra Corp. | -233.46 Thousand USD | -4073.949% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 51.975% |
| PureTech Health plc | -65.69 Million USD | 85.167% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 54.178% |
| IXICO plc | -1.17 Million USD | -727.225% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 1.836% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 82.942% |
| CSL Limited | 2.64 Billion USD | 100.369% |
| Cellectis S.A. | -103.17 Million USD | 90.555% |